Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells

Marker Therapeutics, Inc.

In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.
Initial CAR T administration eliminated 98% of lymphoma cells; resistant population emerged; MT-601 overcame resistance.
MT-601 targets six antigens (including WT-1) vs. five in earlier TACTAL study, potentially offering more durable responses.
FDA cleared IND for MT-601; Phase 1 trial in relapsed non-Hodgkin lymphoma initiated Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.